AstraZeneca PLC (AZN) Stock

NASDAQ
HealthcareDrug Manufacturers - General Website

AZN has an Alpha Score of 41 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 19 members of Congress disclosed 36 trades in AZN since 2014: 18 purchases and 17 sales, most recently Alan Armstrong (purchase, Mar 31, 2026). Its trailing P/E ratio is 26.0 and its net margin 17.7% (key statistics as of Nov 12, 2026).

$174.35
-0.60%
Last price
Source: Finnhub
Alpha Score
41
Weak

What is AZN's Alpha Score?

How it works →

Alpha Score of 41 reflects weak overall profile with weak momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
31
Poor
Value
44
Weak
Quality
64
Moderate

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 21, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded AstraZeneca PLC (AZN)?

Members
19
Disclosed trades
36
Purchases
18
Sales
17

Most recent: Alan Armstrong (purchase, Mar 31, 2026); records start Apr 25, 2014.

PoliticianTrade dateTypeAmount
Alan Armstrong
R-OK · Senate
2026-03-31purchase$1k – $15k
Alan Armstrong
R-OK · Senate
2026-03-30purchase$15k – $50k
Gil Cisneros
D-CA · House
2025-12-18purchase$1k – $15k
Julia Letlow
R-LA · House
2025-12-08purchase$1k – $15k
Gil Cisneros
D-CA · House
2025-11-19purchase$1k – $15k
Lisa McClain
R-MI · House
2025-10-31sale$1k – $15k
Lisa McClain
R-MI · House
2025-10-30purchase$1k – $15k
Lisa McClain
R-MI · House
2025-10-30sale$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded AZN, with filing lags →

Are AstraZeneca PLC insiders buying or selling?

SEC Form 4 filings
DateInsiderRoleTypeSharesValue
Aug 8, 26Sharma ManiSee RemarksBUY20.233$3K

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are AZN's key statistics?

P/E Ratio
26.00
EPS (TTM)
7.07
Dividend Yield
2.30%
Beta
1.31
Net Margin
17.68%
ROE
22.28%
Debt / Equity
0.61
52W High
$15730.00
52W Low
$11404.00

Key statistics as of Nov 12, 2026

How does AZN's valuation compare with the Healthcare sector?

MetricAZNHealthcare medianCompanies in median
P/E ratio26.029.1147
Net margin17.68%3.59%223
Return on equity22.28%3.41%255
Dividend yield (payers)2.30%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.

AZN price chart

Powered by TradingView

What does AstraZeneca PLC do?

AstraZeneca PLC American Depositary Shares represent ownership in AstraZeneca PLC, a multinational biopharmaceutical company headquartered in Cambridge, United Kingdom. The company focuses on the discovery, development, manufacture, and commercialization of prescription medicines across key therapeutic areas. Oncology constitutes its largest segment, featuring products like Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap. Other core areas include cardiovascular, renal, and metabolic medicines such as Farxiga and Brilinta; rare disease therapies like Ultomiris and Soliris; and respiratory and immunology treatments including Symbicort, Fasenra, and Breztri. AstraZeneca PLC also offers vaccines and immune therapies. It serves primary and specialty care physicians globally through distributors and local offices, with significant presence in the United States, Europe, and Asia. This structure positions AstraZeneca PLC as a major player in the global pharmaceutical industry, addressing diverse medical needs in oncology, rare diseases, and chronic conditions.

CEO
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Employees
96,100
Market Cap
$215.33B
Ask about AZNAI research agent